Literature DB >> 17725718

How we treat: management of life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol.

Matthew Burtelow1, Ed Riley, Maurice Druzin, Magali Fontaine, Maurene Viele, Lawrence Tim Goodnough.   

Abstract

Management of massive, life-threatening primary postpartum hemorrhage in the labor and delivery service is a challenge for the clinical team and hospital transfusion service. Because severe postpartum obstetrical hemorrhage is uncommon, its occurrence can result in emergent but variable and nonstandard requests for blood products. The implementation of a standardized massive transfusion protocol for the labor and delivery department at our institution after a maternal death caused by amniotic fluid embolism is described. This guideline was modeled on a existing protocol used by the trauma service mandating emergency release of 6 units of group O D- red cells (RBCs), 4 units of fresh frozen or liquid plasma, and 1 apheresis unit of platelets (PLTs). The 6:4:1 fixed ratio of uncrossmatched RBCs, plasma, and PLTs allows the transfusion service to quickly provide blood products during the acute phase of resuscitation and allows the clinical team to anticipate and prevent dilutional coagulopathy. The successful management of three cases of massive primary postpartum hemorrhage after the implementation of our new massive transfusion protocol in the maternal and fetal medicine service is described.

Entities:  

Mesh:

Year:  2007        PMID: 17725718     DOI: 10.1111/j.1537-2995.2007.01404.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

1.  Thrombelastography Should Be Included in the Algorithm for the Management of Postpartum Hemorrhage.

Authors:  Csilla Jámbor; Sybille A Kozek-Langenecker; Thomas Frietsch; Ralf Knels
Journal:  Transfus Med Hemother       Date:  2008-09-16       Impact factor: 3.747

2.  Development of a scoring system to predict massive postpartum transfusion in placenta previa totalis.

Authors:  Jung-Won Kim; Yoon-Kyung Lee; Ji-Hyun Chin; Seon-Ok Kim; Mi-Young Lee; Hye-Sung Won; Woo-Jong Choi
Journal:  J Anesth       Date:  2017-05-02       Impact factor: 2.078

Review 3.  Transfusion and coagulation management in major obstetric hemorrhage.

Authors:  Alexander J Butwick; Lawrence T Goodnough
Journal:  Curr Opin Anaesthesiol       Date:  2015-06       Impact factor: 2.706

Review 4.  RBC Transfusion Strategies in the ICU: A Concise Review.

Authors:  Casey A Cable; Seyed Amirhossein Razavi; John D Roback; David J Murphy
Journal:  Crit Care Med       Date:  2019-11       Impact factor: 7.598

Review 5.  Massive transfusion protocols for patients with substantial hemorrhage.

Authors:  Pampee P Young; Bryan A Cotton; Lawrence T Goodnough
Journal:  Transfus Med Rev       Date:  2011-06-12

6.  Perioperative and transfusion outcomes in women undergoing cesarean hysterectomy for abnormal placentation.

Authors:  Kathleen F Brookfield; Lawrence T Goodnough; Deirdre J Lyell; Alexander J Butwick
Journal:  Transfusion       Date:  2013-11-04       Impact factor: 3.157

7.  Recombinant Factor VIIa in Post-partum Hemorrhage: A New Weapon in Obstetrician's Armamentarium.

Authors:  Navneet Magon; Km Babu
Journal:  N Am J Med Sci       Date:  2012-04

Review 8.  Recombinant activated factor VII in post partum haemorrhage.

Authors:  Navneet Magon; K M Babu; Krishan Kapur; Sanjiv Chopra; Gurdarshan Singh Joneja
Journal:  Niger Med J       Date:  2013-09

Review 9.  Management of postpartum haemorrhage.

Authors:  Marie Pierre Bonnet; Dan Benhamou
Journal:  F1000Res       Date:  2016-06-27

10.  Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum Hemorrhage.

Authors:  Dacia D C A Henriquez; Camila Caram-Deelder; Saskia le Cessie; Joost J Zwart; Jos J M van Roosmalen; Jeroen C J Eikenboom; Cynthia So-Osman; Leo M G van de Watering; Jaap Jan Zwaginga; Ankie W M M Koopman-van Gemert; Kitty W M Bloemenkamp; Johanna G van der Bom
Journal:  JAMA Netw Open       Date:  2019-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.